Neulasta Articles
Kyowa Hakko set to file for pegfilgrastim approval in Japan following strong Ph III data
28 January 2013
Sandoz initiates two more Phase III biosimilar trials
20 January 2012
Amgen's fourth quarter 2009 earnings slightly below consensus analyst’s expectations
26 January 2010
Teva files BLA for XM02 with FDA for chemotherapy-induced neutropenia; a challenge to Amgen’s Neupogen?
2 December 2009
Cost-cutting helps Amgen lift 3rd quarter 2009 EPS 21%
22 October 2009
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will erode $8.2 billion in US and European sales in 2018
17 September 2009
Falling profit on low sales for Amgen
27 April 2009
Amgen's 3rd-qtr 2008 profit leaps to $1.16B
3 November 2008
Amgen earnings down but outlook still up
4 August 2008
Amgen and Ortho Bio settle antitrust suit
21 July 2008
Amgen reports nearly flat 1st qtr
5 May 2008
French drug sales rose 4%-4.5% in 2007
21 January 2008
Amgen issued with subpoenas
19 November 2007
Amgen's 1st-qtr 2007 net profits up 11%
30 April 2007
Ratiopharm unit and Neose initiate Ph I study
26 March 2007
Amgen's 2nd-qtr 2006 sales up 14% to $3.6B
31 July 2006
Amgen sees $1B profits in 1st-qtr 2006
24 April 2006
Amgen starts $1B Puerto Rico site expansion
13 February 2006
FDA licenses to Amgen production facilities
12 September 2005
Stock Commentary - New York
18 July 2005
Amgen posts 26% EPS hike, raises forecast
25 April 2005
Amgen's 2nd-qtr 2004 EPS jumps 27%
9 August 2004
Strong sales boost Amgen profit
2 February 2004
Amgen forecasts 18%-30% rise in 2004 profits, boosted by lead drugs
22 December 2003
Profits up at Amgen on strong sales growth
27 October 2003
Amgen outperforms in 1st qtr, raises forecast
28 April 2003
New report sees big changes for global antibiotics market
10 February 2003
Aranesp gets CPMP backing for two drugs
10 June 2002
Amgen buys filgrastim rights for $137 million
13 May 2002
Amgen's celebrity marketing of Neulasta
29 April 2002
Stock Commentary - New York
11 February 2002
Amgen gets US OK for pegfilgrastim
11 February 2002
FDA approves Amgen's new-generation filgrastim product, Neulasta
11 February 2002
Amgen says pegfilgrastim as effective as filgrastim in neutropenia
13 December 2001
Amgen expecting strong sales and earnings growth in 2002
22 November 2001
Aranesp equivalent to Epogen in Ph III trial
15 May 2001
Amgen's 1st-qtr net income rises 15%
1 May 2001
Amgen notes delay in launch of Aranesp
1 May 2001
Showing 1-54 of 54 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
